The evidence pertaining to psychostimulant withdrawal is sparse in comparison to that available for alcohol and opioid withdrawal. No studies describing the natural history of withdrawal among methamphetamine-dependent persons have been published. Recommendations for psychostimulant detoxification and withdrawal management, the presentation of which is a mixture of CNS hypoactivity with irritability and insomnia of variable duration, tend to be based on clinical opinion and therefore management strategies may vary from setting to setting. The role of pharmacotherapies is currently limited, however benzodiazepines, antipsychotics and antidepressants if necessary are currently considered by clinicians to be the major components of a medicated psychostimulant withdrawal program. Prospective studies into cocaine and amphetamine (particularly methamphetamine) detoxification and withdrawal management with mixed gender samples of outpatients and in-patients are required to inform Australian service development and appropriate responses.